AbbVie M12-914 A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Cancer - Breast,
D’Amour Cancer Center for Care
3350 Main Street
Springfield, MA 01199
The main purpose of the study is to determine if veliparib in combination with carboplatin and paclitaxel improves the efficacy of chemotherapy alone in participants with a BRCA1 or BRCA2 mutation and HER2-negative metastatic or locally advanced breast cancer.
BRCA1/BRCA2, HER2- negative, metastatic/locally advanced breast cancer
Rae Lynn Defeo